SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+12.63%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$638M
AUM Growth
+$638M
(+6%)
Cap. Flow
-$34.8M
Cap. Flow
% of AUM
-5.46%
Top 10 Holdings %
Top 10 Hldgs %
67.85%
Holding
37
New
5
Increased
15
Reduced
10
Closed
6
Top Buys
| 1 |
Agilent Technologies
A
|
$15M |
| 2 |
Incyte
INCY
|
$14.8M |
| 3 |
Biogen
BIIB
|
$12.7M |
| 4 |
Perrigo
PRGO
|
$8.06M |
| 5 |
SHPG
Shire pic
SHPG
|
$6.06M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$24.4M |
| 2 |
Eli Lilly
LLY
|
$18M |
| 3 |
Merck
MRK
|
$13M |
| 4 |
Bristol-Myers Squibb
BMY
|
$11.3M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$9.83M |
Sector Composition
| 1 | Healthcare | 98.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Abbott
ABT
$231B
| $72.1M | 11.3% | 982,312 -82,250 | -8% | -$6.03M |
|
2
Baxter International
BAX
$12.7B
| $54.4M | 8.54% | 706,228 -14,830 | -2% | -$1.14M |
|
3
Boston Scientific
BSX
$156B
| $53.3M | 8.35% | 1,383,374 -77,926 | -5% | -$3M |
|
|
4
Merck
MRK
$210B
| $51.9M | 8.13% | 731,046 -182,784 | -20% | -$13M |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $44.8M | 7.02% | 720,880 -181,346 | -20% | -$11.3M |
|
|
SHPG
6
DELISTED
Shire pic
SHPG
| $37.2M | 5.83% | 205,256 +33,431 | +19% | +$6.06M |
|
7
Revvity
RVTY
$10.5B
| $35.9M | 5.63% | 369,081 +6,125 | +2% | +$596K |
|
8
Bio-Rad Laboratories Class A
BIO
$8.06B
| $30.3M | 4.75% | 96,697 +10,248 | +12% | +$3.21M |
|
|
NUVA
9
DELISTED
NuVasive, Inc.
NUVA
| $28.1M | 4.4% | 395,223 +19,416 | +5% | +$1.38M |
|
10
Gilead Sciences
GILD
$140B
| $25M | 3.91% | 323,187 +31,587 | +11% | +$2.44M |
|
11
Elevance Health
ELV
$71.8B
| $22.9M | 3.59% | 83,513 -4,397 | -5% | -$1.21M |
|
12
Integra LifeSciences
IART
$1.18B
| $22.3M | 3.5% | 338,733 +12,074 | +4% | +$795K |
|
|
13
Perrigo
PRGO
$3.27B
| $22.2M | 3.48% | 313,220 +113,780 | +57% | +$8.06M |
|
|
14
Agilent Technologies
A
$35.7B
| $15M | 2.36% | +213,300 | New | +$15M |
|
|
15
Incyte
INCY
$16.5B
| $14.8M | 2.32% | +213,764 | New | +$14.8M |
|
16
Universal Health Services
UHS
$11.6B
| $13.4M | 2.1% | 105,012 +6,379 | +6% | +$816K |
|
|
17
Biogen
BIIB
$19.4B
| $12.7M | 1.99% | +36,000 | New | +$12.7M |
|
|
PDCO
18
DELISTED
Patterson Companies, Inc.
PDCO
| $11.7M | 1.83% | 477,707 +165,475 | +53% | +$4.05M |
|
19
Ionis Pharmaceuticals
IONS
$6.79B
| $10.4M | 1.64% | 202,434 -100,806 | -33% | -$5.2M |
|
20
Lexicon Pharmaceuticals
LXRX
$400M
| $9.2M | 1.44% | 862,602 | – | – |
|
21
Cardinal Health
CAH
$35.5B
| $7.36M | 1.15% | 136,335 +10,072 | +8% | +$544K |
|
|
22
AstraZeneca
AZN
$248B
| $7.24M | 1.13% | 182,905 -617,683 | -77% | -$24.4M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.18M | 1.13% | 269,701 +68,901 | +34% | +$1.83M |
|
24
Dr. Reddy's Laboratories
RDY
$11.8B
| $5.92M | 0.93% | +171,219 | New | +$5.92M |
|
|
CLVS
25
DELISTED
Clovis Oncology, Inc.
CLVS
| $5.45M | 0.85% | 185,577 +11,685 | +7% | +$343K |
|